BR112022020486A2 - Imunoterapia específica de antígeno para proteínas de fusão de covid-19 e métodos de uso - Google Patents

Imunoterapia específica de antígeno para proteínas de fusão de covid-19 e métodos de uso

Info

Publication number
BR112022020486A2
BR112022020486A2 BR112022020486A BR112022020486A BR112022020486A2 BR 112022020486 A2 BR112022020486 A2 BR 112022020486A2 BR 112022020486 A BR112022020486 A BR 112022020486A BR 112022020486 A BR112022020486 A BR 112022020486A BR 112022020486 A2 BR112022020486 A2 BR 112022020486A2
Authority
BR
Brazil
Prior art keywords
covid
fusion proteins
cov
sars
patients
Prior art date
Application number
BR112022020486A
Other languages
English (en)
Inventor
C Zion Todd
M Lancaster Thomas
Sathiyaseelan Thillainayagam
Huang Kexin
Original Assignee
Akston Biosciences Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akston Biosciences Corp filed Critical Akston Biosciences Corp
Publication of BR112022020486A2 publication Critical patent/BR112022020486A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6056—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

IMUNOTERAPIA ESPECÍFICA DE ANTÍGENO PARA PROTEÍNAS DE FUSÃO DE COVID-19 E MÉTODOS DE USO. A presente descrição provê proteínas de fusão recombinantemente fabricadas compreendendo um fragmento do Domínio de Ligação de Receptor do SARS-CoV-2 (SARS-CoV-2-RBD) ou um análogo do mesmo ligado a um fragmento Fc humano para o uso em relação ao Novo Coronavírus 2019 (COVID-19). As modalidades incluem a administração das proteínas de fusão aos pacientes que se recuperaram de COVID-19 como uma vacinação de reforço, aos pacientes ingênuos em anticorpo para produzir anticorpos para o vírus SARS-CoV-2 para permitir que os pacientes de tornem doadores de plasma convalescente, aos pacientes que foram infectados pelo vírus SARS-CoV-2 e contraíram COVID-19 de modo a limitar o âmbito da infecção e melhorar a doença e como uma vacina profilática contra o COVID-19. As proteínas de fusão Fc exemplares e formulações farmacêuticas de proteínas de fusão Fc exemplares são providas, além de métodos de uso e preparação.
BR112022020486A 2020-04-10 2021-04-09 Imunoterapia específica de antígeno para proteínas de fusão de covid-19 e métodos de uso BR112022020486A2 (pt)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US202063008509P 2020-04-10 2020-04-10
US202063008515P 2020-04-10 2020-04-10
US202063008497P 2020-04-10 2020-04-10
US202063008503P 2020-04-10 2020-04-10
US202063041584P 2020-06-19 2020-06-19
US202063041574P 2020-06-19 2020-06-19
US202063041579P 2020-06-19 2020-06-19
US202063041582P 2020-06-19 2020-06-19
US202063048939P 2020-07-07 2020-07-07
US202063068911P 2020-08-21 2020-08-21
US202063068805P 2020-08-21 2020-08-21
US202063068894P 2020-08-21 2020-08-21
US202063068843P 2020-08-21 2020-08-21
US202063068775P 2020-08-21 2020-08-21
PCT/US2021/026577 WO2021207599A1 (en) 2020-04-10 2021-04-09 Antigen specific immunotherapy for covid-19 fusion proteins and methods of use

Publications (1)

Publication Number Publication Date
BR112022020486A2 true BR112022020486A2 (pt) 2023-01-17

Family

ID=75640036

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022020486A BR112022020486A2 (pt) 2020-04-10 2021-04-09 Imunoterapia específica de antígeno para proteínas de fusão de covid-19 e métodos de uso

Country Status (17)

Country Link
US (3) US11213581B2 (pt)
EP (2) EP3972987B1 (pt)
JP (1) JP2023522597A (pt)
KR (1) KR20220167317A (pt)
CN (1) CN116096733A (pt)
AU (2) AU2021253926B2 (pt)
BR (1) BR112022020486A2 (pt)
CA (1) CA3146464C (pt)
DK (1) DK3972987T3 (pt)
FI (1) FI3972987T3 (pt)
HR (1) HRP20230990T1 (pt)
HU (1) HUE062716T2 (pt)
IL (1) IL297064A (pt)
LT (1) LT3972987T (pt)
SI (1) SI3972987T1 (pt)
WO (1) WO2021207599A1 (pt)
ZA (1) ZA202210992B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112500498B (zh) * 2020-02-26 2022-09-06 四川大学 新型冠状病毒疫苗及其制备方法和应用
CA3146464C (en) * 2020-04-10 2024-03-12 Todd C. Zion Antigen specific immunotherapy employing covid-19 fusion proteins and methods of use
US20240042013A1 (en) * 2020-12-16 2024-02-08 Instituto Finlay De Vacunas Use of vaccine compositions based on sars-cov-2 receptor binding domain in delivering protective immunity
JP2024502783A (ja) * 2020-12-23 2024-01-23 ザ ユニバーシティー オブ メルボルン コロナウイルスワクチン
KR20220109996A (ko) * 2021-01-29 2022-08-05 (주)셀트리온 사스-코로나바이러스-2 융합 단백질 및 이를 포함하는 면역원성 조성물
CN114014940B (zh) * 2021-11-25 2022-11-15 华兰基因工程有限公司 一种2019-nCoV表面蛋白受体结合区融合蛋白制备方法
CN113980135B (zh) * 2021-12-27 2022-04-19 三优生物医药(上海)有限公司 一种结合冠状病毒双特异性抗体的抗药抗体及其制备方法和应用
WO2023154402A2 (en) * 2022-02-09 2023-08-17 University Of Maryland, College Park Compositions and methods for fcrn-targeted intranasal coronavirus vaccination
WO2023212579A1 (en) * 2022-04-25 2023-11-02 Boost Biopharma, Inc. Recombinant polypeptides containing at least one immunogenic fragment and uses thereof
KR20240009373A (ko) * 2022-07-12 2024-01-22 에스케이바이오사이언스(주) SARS-CoV-2 백신 부스터 조성물

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030040601A1 (en) 2001-06-08 2003-02-27 Ivan Diers Method for making insulin precursors and insulin analog precursors
KR20080050576A (ko) * 2005-07-29 2008-06-09 앰프로틴 코포레이션 키메릭 치료제
US8569231B2 (en) 2009-03-20 2013-10-29 Smartcells, Inc. Soluble non-depot insulin conjugates and uses thereof
EP2413969A4 (en) 2009-03-30 2012-09-05 Boehringer Ingelheim Int FUSION PROTEINS WITH DOG FC ELEMENTS
CN101891823B (zh) 2010-06-11 2012-10-03 北京东方百泰生物科技有限公司 一种Exendin-4及其类似物融合蛋白
CA2805739A1 (en) 2010-07-28 2012-02-02 Smartcells, Inc. Drug-ligand conjugates, synthesis thereof, and intermediates thereto
WO2012015692A2 (en) 2010-07-28 2012-02-02 Smartcells, Inc. Recombinantly expressed insulin polypeptides and uses thereof
AR087433A1 (es) 2011-08-08 2014-03-26 Merck Sharp & Dohme Analogos de insulina n-glicosilados
EP2780463A4 (en) 2011-11-18 2015-07-01 Merck Sharp & Dohme FC-CONTAINING POLYPEPTIDES WITH INCREASED INFLAMMATORY FEATURES AND INCREASED FCRN BINDING
KR102041412B1 (ko) 2011-12-30 2019-11-11 한미사이언스 주식회사 면역글로불린 Ｆｃ 단편 유도체
CN103509118B (zh) 2012-06-15 2016-03-23 郭怀祖 胰岛素-Fc融合蛋白
ES2868351T3 (es) 2013-02-26 2021-10-21 Hanmi Pharm Ind Co Ltd Conjugados de análogos de insulina y usos de los mismos
CN105934441A (zh) 2013-11-26 2016-09-07 贝勒医学院 新型sars免疫原性组合物
US10287336B2 (en) 2014-09-18 2019-05-14 AskGene Pharma, Inc. Feline erythropoietin receptor agonists
WO2016105545A2 (en) 2014-12-24 2016-06-30 Case Western Reserve University Insulin analogues with enhanced stabilized and reduced mitogenicity
EP3250589A4 (en) 2015-01-29 2018-06-20 Nexvet Australia Pty Ltd Therapeutic and diagnostic agents
EP3260139A4 (en) 2015-02-17 2018-09-05 Hanmi Pharm. Co., Ltd. Long-acting insulin or insulin analogue complex
AU2016257000B2 (en) 2015-05-04 2020-05-14 Apogenix Ag Single-chain CD40-receptor agonist proteins
AR105616A1 (es) 2015-05-07 2017-10-25 Lilly Co Eli Proteínas de fusión
US11208452B2 (en) 2015-06-02 2021-12-28 Novo Nordisk A/S Insulins with polar recombinant extensions
CN114835795A (zh) 2015-11-16 2022-08-02 Ubi蛋白公司 用于延长蛋白质半衰期的方法
WO2018009921A1 (en) 2016-07-08 2018-01-11 AskGene Pharma, Inc. Fusion protein comprising leptin and methods for producing and using the same
EP3517544A4 (en) 2016-09-23 2020-06-03 Hanmi Pharm. Co., Ltd. INSULIN ANALOG HAVING REDUCED INSULIN RECEPTOR BINDING FORCE AND USE THEREOF
WO2018073185A1 (en) 2016-10-17 2018-04-26 Vetoquinol Sa Modified antibody constant region
SI3551209T1 (sl) 2016-12-09 2021-10-29 Akston Biosciences Corp Inzulin-FC fuzije in postopki uporabe
UY37629A (es) 2017-03-07 2018-10-31 Univ Case Western Reserve Análogos de insulina de cadena simple estabilizados por un cuarto puente disulfuro
JP2020531002A (ja) 2017-08-15 2020-11-05 キンドレッド バイオサイエンシズ インコーポレイテッド 獣医学用ｉｇｇ ｆｃ変異体
EP3781147A4 (en) 2018-04-16 2022-04-20 University of Utah Research Foundation GLUCOSE-SENSITIVE INSULIN
US11696948B2 (en) * 2018-06-12 2023-07-11 Kbio Holdings Limited Vaccines formed by virus and antigen conjugation
HRP20221418T1 (hr) 2018-06-29 2023-01-06 Akston Biosciences Corporation Inzulin-fc fuzijski proteini ultra-dugog djelovanja i postupci uporabe
US11267862B2 (en) 2018-06-29 2022-03-08 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
CA3114395A1 (en) 2018-09-25 2020-04-02 Absci, Llc Protein purification methods
MA53809A (fr) 2018-10-05 2022-01-12 Novo Nordisk As Composés bifonctionnels comprenant des peptides d'insuline et des peptides d'egf(a)
WO2020106748A1 (en) 2018-11-19 2020-05-28 Case Western Reserve University Single-chain insulin analogues with poly-alanine c-domain sub-segments
US20220235111A1 (en) 2019-05-17 2022-07-28 Case Western Reserve University Variant Single-Chain Insulin Analogues
WO2021011827A1 (en) 2019-07-16 2021-01-21 Akston Biosciences Corporation Ultra-long acting insulin-fc fusion proteins and methods of use
EP4004028A1 (en) 2019-07-31 2022-06-01 Eli Lilly and Company Relaxin analogs and methods of using the same
HRP20231433T1 (hr) 2019-12-19 2024-03-29 Akston Biosciences Corporation Inzulin-fc fuzijski proteini ultradugog djelovanja i načini uporabe
US11186623B2 (en) 2019-12-24 2021-11-30 Akston Bioscience Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
CN111333704B (zh) 2020-02-24 2021-01-12 军事科学院军事医学研究院微生物流行病研究所 新型冠状病毒covid-19疫苗、制备方法及其应用
CA3146464C (en) * 2020-04-10 2024-03-12 Todd C. Zion Antigen specific immunotherapy employing covid-19 fusion proteins and methods of use
US11192930B2 (en) 2020-04-10 2021-12-07 Askton Bioscences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
US11198719B2 (en) 2020-04-29 2021-12-14 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
CN111647077B (zh) * 2020-06-02 2021-02-09 深圳市因诺赛生物科技有限公司 新型冠状病毒(sars-cov-2)刺突蛋白结合分子及其应用
CN112480268B (zh) * 2020-12-10 2021-08-03 北京康乐卫士生物技术股份有限公司 一种新型冠状病毒的重组亚单位疫苗及其应用

Also Published As

Publication number Publication date
HRP20230990T1 (hr) 2023-12-08
HUE062716T2 (hu) 2023-11-28
AU2021253926B2 (en) 2022-07-21
US20240016921A1 (en) 2024-01-18
AU2022231665B2 (en) 2024-02-22
JP2023522597A (ja) 2023-05-31
EP3972987A1 (en) 2022-03-30
ZA202210992B (en) 2023-08-30
WO2021207599A1 (en) 2021-10-14
CA3146464A1 (en) 2021-10-14
US11707517B2 (en) 2023-07-25
AU2021253926A1 (en) 2022-02-24
FI3972987T3 (fi) 2023-07-25
CN116096733A (zh) 2023-05-09
EP3972987B1 (en) 2023-06-07
KR20220167317A (ko) 2022-12-20
LT3972987T (lt) 2023-09-25
US11213581B2 (en) 2022-01-04
US20220088182A1 (en) 2022-03-24
CA3146464C (en) 2024-03-12
IL297064A (en) 2022-12-01
EP4248983A2 (en) 2023-09-27
WO2021207599A9 (en) 2022-01-06
DK3972987T3 (da) 2023-07-31
AU2022231665A1 (en) 2022-10-06
SI3972987T1 (sl) 2023-10-30
US20210346490A1 (en) 2021-11-11
EP4248983A3 (en) 2024-01-24

Similar Documents

Publication Publication Date Title
BR112022020486A2 (pt) Imunoterapia específica de antígeno para proteínas de fusão de covid-19 e métodos de uso
Weldon et al. Microneedle vaccination with stabilized recombinant influenza virus hemagglutinin induces improved protective immunity
Abeck et al. Quadrivalent human papillomavirus vaccination: a promising treatment for recalcitrant cutaneous warts in children
ES2440974T3 (es) Constructos poliepitópicos del VPH y uso de los mismos
SG131116A1 (en) Functional influenza virus-like particles (vlps)
CN1678344A (zh) 人***状瘤病毒治疗
BR0209837A (pt) Partìcula semelhante a vìrus isolada ou recombimante capaz de replicação, composição, e, método para inibir ou bloquear uma infecção com um coronavìrus ou partìcula semelhante a coronavìrus
Joyce et al. Extended delivery of vaccines to the skin improves immune responses
BR112013029417A2 (pt) composições de vacina de matriz proteica incluindo policátions
JP6941566B2 (ja) 固定化ウイルス粒子を含むワクチン
Christensen et al. Syringe free vaccination with CAF01 Adjuvated Ag85B-ESAT-6 in Bioneedles provides strong and prolonged protection against tuberculosis
CN106749594A (zh) 包含f1、f3多肽的药物组合物及其在治疗hpv感染疾病中的应用
BRPI0606165A2 (pt) método de indução de uma resposta imunológica de célula t de memória contra pelo menos um antìgeno em um paciente humano, uso de uma composição imunogênica que compreende um vetor de vìrus de infecção virulenta não-replicante ou emparelhado de replicação que expressa o produto de tradução de um gene de ag85a micobacterial, uso de um antìgeno na manufatura de um medicamento para o tratamento de uma doença em um paciente mediante a indução de uma resposta imunológica de célula t de memória central e vacina vetorada
Wang et al. Virus‐Like Particles Containing the Tetrameric Ectodomain of Influenza Matrix Protein 2 and Flagellin Induce Heterosubtypic Protection in Mice
Stewart et al. ISCOMATRIX™ adjuvant: an adjuvant suitable for use in anticancer vaccines
Namvarpour et al. Comparison of different immunization routes on the immune responses induced by Mycobacterium tuberculosis ESAT-6/CFP-10 recombinant protein
AU2008265367B2 (en) Capsid proteins and uses therefore
TW201601750A (zh) 注射疫苗組合物
Gilbert et al. Safety and immunogenicity of a modified process hepatitis B vaccine in healthy adults≥ 50 years
BR112023019967A2 (pt) Composto de tetra-hidronaftaleno e método de preparação para o mesmo e uso do mesmo em medicina
Aricò et al. Exploiting natural antiviral immunity for the control of pandemics: lessons from Covid-19
JP6940649B2 (ja) 皮内投与インフルエンザワクチン組成物
PE20230349A1 (es) Vacunas para la papilomatosis respiratoria recurrente y metodos para usar estas
CN106535933B (zh) 包含核受体配体的免疫诱导促进用组合物以及疫苗药物组合物
BR112022001070A2 (pt) Composição de imunogenicidade polivalente para papilomavírus humano